 I'm Jay Barkley, I'm a Professor of Pediatric Infectious Diseases. I've been based at the overseas programme in Kilifi for about 21 years. My research is really in causes of death and things that we can do about preventing deaths in the most vulnerable groups of children in developing countries. In a broad sense it's addressing groups such as children with malnutrition or newborn infants. But more specifically my main focus is on infections and antibiotic trials to try and improve treatment of severe infections in children. So although there's been progress in reducing child mortality we still see a very high mortality rate particularly in newborns. But there are also other high-risk groups in whom we don't seem to see any reduction in the fatality rates when children get admitted to hospital. The other thing that's emerged from recent research from our group and from other groups is that after children are discharged from hospital there's still considerable mortality. So some of the studies that we've done have shown that for every one child who dies in hospital another one dies post-discharge. So a big focus of our research is also understanding the post-discharge period. Is it something that's a problem that hasn't been treated sufficiently in hospital or is it something about the child's environment or another infection that they're exposed to? So understanding those helps us understand how to make the treatments more effective. So that's our aim is to fight tropical illnesses. The largest study we do which is the chain network which is the childhood acute illness and nutrition network is a study that's at typical hospitals across nine sites in Africa and in South Asia. And in those sites we're looking at what are the potentially preventable causes of mortality in children after all of the recommended treatments have been applied. So at the sites we make sure that their following guidelines and treatments are available we then follow a large cohort of about 4,000 children who are at increased risk of mortality to see what factors are leading to an increased risk of mortality in hospital and after discharge with the purpose of then taking some of the findings into clinical trials in order to directly improve outcomes. We've just finished a small but intensive trial of a potentially new antibiotic treatment for neonatal sepsis and we're doing a very large trial of first line antibiotics for severely ill malnarsh children. Now we're doing those trials because there's an emerging increasing problem with antimicrobial resistance. In the settings where we work typically people don't have any information on what exact bacteria are causing illness and what the sensitivity or resistance to antibiotics is. So we need policies which are going to be able to be used in those typical settings. And these are settings where the vast majority of children are treated. There are some information around but they typically come from university hospitals or private hospitals where only a tiny proportion of children get treated. So by investing in research in that more generalizable population we're providing information and improvements in guidelines and knowledge which will improve outcomes in a much broader sense. With regards to translation we do a lot of work in the laboratory. Firstly we do a lot of work on characterising what kinds of infections children have. Sometimes that uses the normal microbiology techniques and sometimes that uses much more advanced modern molecular techniques for detecting bacteria, for detecting resistance and detecting other kinds of infections. We also do a lot of work with partners overseas and other labs looking at the effect that under nutrition and infections have on children's metabolism. By getting this very detailed data and putting it together with the detailed information that we collect from the children themselves we're then able to look at what pathways might be intervenable. So what pathways could be interrupted or changed which would then improve outcomes and so we can translate those findings from the laboratory into initially small trials where we look at safety or look at whether or not the pathways are being affected and then into larger trials to go into policy to improve outcomes.